News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Ablynx (ABLYF) Announces Update on Anti-RSV Nanobody Programme and Receives Grant Funding for Further Development



10/31/2013 10:21:14 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

GHENT, Belgium, Oct. 31, 2013 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels:ABLX] today announced that it has received notice of a €1.68 million in grant funding from the Flemish Agency for Innovation by Science and Technology (IWT) to help advance the Company's first inhaled Nanobody®, ALX-0171, in infants. The grant funding, which is available over a period of one year, will also be used to explore novel applications of nebulised Nanobodies.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
Ablynx
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES